Filing Flows › Health Care › Smith & Nephew (SNN)
Smith & Nephew (SNN) earnings and revenue breakdown
Latest: H1 2026 · 6-K filed Aug 14, 2026 · Smith & Nephew (SNN) H1 2026 earnings results →
H1 2026 Revenue up 5% year over year to $3.1B · 10¢ of every $1 of revenue kept as net profit · operating margin 14.5%
Smith & Nephew made $3.1B in H1 2026 (+5% Y/Y). Operating margin 14.5%, net earnings $303M. See where every dollar goes — costs, profit and cash — as a Sankey from the 6-K filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3.1B in H1 2026, up 5% year over year.
Gross margin was 70.9%, up 0.3 points from a year earlier. Operating profit was $0.45B, a 14.5% margin (unchanged year over year). Of the extra revenue versus a year earlier, 14% reached operating profit, below the 14% margin then. Operating expenses grew 5% against revenue growth of 5%. Net earnings were $0.30B, up 3% year over year. The effective tax rate was 20.3%.
Operating cash flow was $0.45B (up 14% year over year), 149% of net earnings. Non-cash charges added back $0.03B of share-based compensation. Working capital and other items added $0.11B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| H1 2026 | 6-K | Aug 14, 2026 | $3.1B | +5% | 14.5% | $303M | $450M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Smith & Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
In its own words, from its 6-K, filed Aug 14, 2026.
Smith & Nephew against its Orthopedic, Prosthetic & Surgical Appliances & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +5% against the peers' median +9%. Operating margin: 14.5% against the peers' median 16.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SNN Smith & Nephew | H1 2026 | $3.1B | +5% | 14.5% |
| ISRG Intuitive Surgical | Q3 2026 | $3.0B | +22% | 19.4% |
| ZBH Zimmer Biomet Holdings | Q3 2026 | $2.1B | +3% | 14.9% |
| EW Edwards Lifesciences | Q3 2026 | $1.7B | +10% | 17.4% |
| STE Steris | Q2 FY27 | $1.6B | +9% | 18.5% |
| ALGN Align Technology | Q3 2026 | $1.0B | +2% | 16.7% |
| ENOV Enovis | Q3 2026 | $559M | +2% | 0.6% |
| MSA MSA Safety | Q3 2026 | $536M | +14% | 16.4% |
| CDRE Cadre Holdings | Q3 2026 | $203M | +30% | 14.0% |
Source: Smith & Nephew 6-K on SEC EDGAR · CIK 845982 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
13F: who owns SNN and who is buying
More on SNN
History
Every quarter: H1 2026 results